FY2025 EPS Estimates for TARA Decreased by Cantor Fitzgerald

Protara Therapeutics, Inc. (NASDAQ:TARA) – Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for Protara Therapeutics in a research note issued on Thursday, March 20th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings per share of ($1.71) for the year, down from their previous forecast of ($1.62). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share.

A number of other research analysts have also weighed in on TARA. Lifesci Capital initiated coverage on shares of Protara Therapeutics in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $22.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $23.00 price objective on shares of Protara Therapeutics in a research report on Thursday, March 6th. Finally, Guggenheim restated a “buy” rating and issued a $20.00 target price on shares of Protara Therapeutics in a report on Friday, December 6th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Protara Therapeutics has an average rating of “Buy” and an average price target of $22.50.

Protara Therapeutics Trading Up 0.6 %

TARA opened at $4.73 on Monday. Protara Therapeutics has a twelve month low of $1.60 and a twelve month high of $10.48. The firm has a market capitalization of $173.91 million, a PE ratio of -1.68 and a beta of 1.69. The firm’s 50-day moving average price is $4.27 and its 200 day moving average price is $3.62.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings data on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.09.

Institutional Trading of Protara Therapeutics

Several institutional investors have recently made changes to their positions in TARA. RA Capital Management L.P. grew its position in Protara Therapeutics by 78.9% in the fourth quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company’s stock worth $17,952,000 after acquiring an additional 1,500,000 shares during the period. Janus Henderson Group PLC purchased a new position in shares of Protara Therapeutics during the 4th quarter worth $11,938,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of Protara Therapeutics during the 4th quarter worth $11,880,000. Toronto Dominion Bank acquired a new stake in shares of Protara Therapeutics during the 4th quarter worth about $11,030,000. Finally, Blackstone Inc. purchased a new stake in Protara Therapeutics in the 4th quarter valued at about $8,870,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.